(C) Specific IgG titers (mg/mL) at baseline, as well as 4 and 8 weeks following type B vaccination in 17 daratumumab-treated RRMM patients
(C) Specific IgG titers (mg/mL) at baseline, as well as 4 and 8 weeks following type B vaccination in 17 daratumumab-treated RRMM patients. during daratumumab therapy. In addition, daratumumab-treated RRMM patients produced protective IgG antibody titers following vaccination against type B and seasonal influenza, to a similar extent as observed in daratumumab-na?ve RRMM patients. We … Read more